FDA Issues Warning about Drug Librela Used to Control Pain in Dogs

Newsweek - Dec 18th, 2024

The FDA's Center for Veterinary Medicine issued a warning to veterinarians about adverse effects in dogs following the use of Librela, a pain relief treatment for osteoarthritis. The warning follows reports of neurological and physical side effects, including ataxia, seizures, and even death. Librela, sponsored by Zoetis and approved in May 2023, is a monthly injection that alleviates joint pain by blocking pain signals. Despite its intended benefits, reports have emerged of severe side effects, prompting the FDA to urge veterinarians to report any adverse reactions. The cost of the injections varies, and veterinarians are advised to keep abreast of new information as it becomes available.

Fda Librela Dog Health Osteoarthritis Veterinary Medicine

Story submitted by Fairstory

RATING

7.2

Fair Story

Consider it well-founded

The article provides a detailed overview of the FDA's warning regarding the Librela drug for dogs, highlighting both the benefits and potential risks associated with its use. However, certain areas could benefit from more depth and additional perspectives.

Accuracy

The article appears to accurately report the FDA's warning and includes specific side effects associated with Librela. However, it would be helpful to verify the claims about the Facebook group and the details of the study mentioned.

Balance

The article primarily focuses on the negative aspects of Librela without providing much perspective from Zoetis or veterinarians who may have had positive experiences. Including more balanced views would enhance the article's fairness.

Clarity

The article is generally clear and logically structured, with technical terms explained. However, it could benefit from a slightly more neutral tone when discussing user reports from social media.

Source quality

The article references the FDA and includes data from a study, which suggests credible sourcing. However, it relies on a Facebook group for anecdotal evidence, which may not be a reliable source of information.

Transparency

The article mentions reaching out to Zoetis for comment, indicating an attempt at transparency. However, it does not disclose whether there are any affiliations or conflicts of interest, particularly with the study mentioned.